Tianjin Lisheng Pharmaceutical's low P/E ratio is justified ...
Tianjin Lisheng Pharmaceutical's low P/E ratio is justified by its below-market growth. Investors see limited potential for earnings improvement, keeping the share price at current levels unless medium-term conditions improve.
Investors Don't See Light At End Of Tianjin Lisheng Pharmaceutical Co.,Ltd.'s (SZSE:002393) Tunnel And Push Stock Down 25%
Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates.
Read more
Comment
Sign in to post a comment